Appearance as a Release Test? This is not the Way to get through an Inspection

Recommendation
12/13 November 2025
How to implement EU-GMP Chapter 8
The FDA has issued a Warning Letter to a manufacturer in the USA who has not adequately tested its drug products. And the manufacturer relied on others for supplier qualification.
The company in question put several batches of over-the-counter Mr. Lulu Sunscreen Drops SPF32 on the US market without testing the content of the active ingredients zinc oxide and titanium dioxide. The company does not conduct specified testing procedures prior to release, but only evaluates the medicines for scent, appearance and texture. The results of this assessment are not documented and there are no written procedures for testing and release.
Fittingly, incoming components used to manufacture the medicines were not adequately checked for identity. The associated supplier qualification was non-existent. It was simply assumed that suppliers were audited by others and therefore complied with regulations and ensured the quality of raw materials.
Thus, it is not surprising that a process validation programme is lacking and data to support basic process parameters such as mixing speed, time and temperature are not available.
Related GMP News
22.10.2025EMA Questions & Answers on Mutual Recognition Agreement (MRA) with US updated
22.10.2025FDA continues to take Root Cause Analysis and CAPA very seriously
14.10.2025Two new GDP Non-Compliance Reports from Romania
01.10.2025Alternative Inspection Methods of the FDA
24.09.2025FDA issues final Guidance on Remote Oversight Tools
24.09.2025Four Warning Letter concerning CAPA and Root Cause Analysis published


